A frank discussion about the recently Japan-approved treatment for ALS, Radicut (Mitsubishi Tanabe), the recently USA-compassionate use approved Masitinib (AB Science) and the results from the USA clinical trial of NurOwn (Brainstorm Cell Therapeutics).
An overview of each from a mechanism of action and known trial data will be provided followed by discussion about next steps for these proposed ALS therapeutics.
Tools for getting into currently enrolling clinical trials, such as tirasemtiv (Cytokinetics), will also be provided.
In addition, attendees will learn about an opportunity to advance ALS research through participation in the Precision Medicine Program at the ALS Therapy Development Institute. |